top of page
Anti-PRAME (clone QR005)

Anti-PRAME (clone QR005)

PRAME – A Cancer-Associated Antigen for Melanocytic Lesion Differentiation
PRAME (Preferentially Expressed Antigen in Melanoma) is a cancer-associated antigen preferentially expressed in the nuclei of neoplastic melanocytes. The newly developed anti-PRAME antibody serves as a valuable diagnostic tool, particularly in cases where traditional melanoma markers such as HMB-45, Melan A, and SOX10 do not provide sufficient information for differentiating benign and malignant melanocytic lesions. Additionally, PRAME may serve as a useful marker for assessing margins in known PRAME-positive melanomas.
Sebaceous gland lobules can act as an internal positive control.
Diagnostic Relevance of PRAME in Melanoma
Recent studies indicate that diffuse nuclear immunoreactivity for PRAME is observed in:
✔ 83.2% of primary melanomas
✔ 87% of metastatic melanomas
PRAME expression is present across all melanoma subtypes:
✔ 92.5% in superficial spreading melanoma
✔ 94.4% in acral melanoma
In contrast, 86.4% of cutaneous melanocytic nevi exhibit a complete absence of PRAME staining, reinforcing its significance in distinguishing benign from malignant lesions.
PRAME as a Cancer-Testis Antigen and Immunotherapy Target
PRAME was first identified as a cancer-testis antigen (CTA) through T-cell clone analysis from a patient with metastatic melanoma. Its expression is absent in normal tissues, except for the testes, ovaries, placenta, adrenal glands, and endometrium.
Beyond melanoma, PRAME is expressed in multiple non-melanocytic malignancies, including:
✔ Non-small cell lung carcinoma (NSCLC)
✔ Breast cancer
✔ Renal cell carcinoma
✔ Ovarian cancer
✔ Leukemias
✔ Synovial sarcoma
✔ Myxoid liposarcoma
Due to its distinct expression profile, PRAME is an attractive target for immunotherapy. Numerous clinical trials are underway to explore the potential of CTA-targeted therapies, including PRAME, in cancer treatment.
In addition to its role as a therapeutic target in metastatic melanoma, PRAME is also recognized as a biomarker for metastatic risk in class 1 uveal melanoma.

    • ADVANTAGES OF RECOMBINANT RABBIT MONOCLONAL ANTIBODIES

      Recombinant rabbit monoclonal antibodies—referred to as Q-clones—combine the best properties of both murine monoclonal and rabbit polyclonal antibodies, offering a broader diagnostic potential.

      Key Advantages of Our Next-Generation Recombinant Rabbit Monoclonal Antibodies

      ✔ High Affinity due to rabbit origin, enabling greater sensitivity in assays—these antibodies bind strongly to antigens and maintain their bond even under challenging conditions, unlike low-affinity antibodies.

      ✔ Superior Specificity with reduced risk of cross-reactivity, thanks to their monoclonal nature.

      ✔ Expanded Antigen Recognition—better recognition of diverse antigens and epitopes.

      ✔ Target Epitopes Poorly Recognized by Mouse-Derived Antibodies, improving detection in certain applications.

      ✔ Enhanced Response to Small-Sized Epitopes, making them ideal for challenging targets.

      ✔ Significantly Improved Recognition of Murine Antigens, broadening their usability in research and diagnostics.

      ✔ Lower Background Staining, ensuring cleaner and more reliable results.

      Recombinant vs. Hybridoma Antibody Generation

      ✔ Exceptional Consistency, Specificity, and Sensitivity—eliminating risks of gene loss, mutations, or cell line drift.

      ✔ Reliable and Controlled Production—generated from a unique gene set, ensuring stable antibody performance.

      ✔ Batch-to-Batch Consistency, guaranteeing reproducible results and long-term product availability.

      ✔ Efficient In Vitro High-Throughput Production, allowing easy standardization and scalable antibody expression for any application.

      Recombinant rabbit monoclonal antibodies represent the future of immunohistochemistry, offering unmatched reliability and precision in diagnostic and research settings.

    • [1] Ikeda H et al. (1997). Immunity. 6(2):199-208.
      [2] Lezcano C et al. (2018). Am J Surg Pathol. 42(11):1456-1465.
      [3] Nettersheim D et al. (2016). Br J Cancer. 115(4):454-464.
      [4] Gassenmaier M et al. (2021). Cancers (Basel). 13(15):3864.
      [5] Lozachmeur C et al. (2022): Int Clin Img and Med Rew. 2(4): 1088.
      [6| Koch EAT et al. (2023): Int J Mol Sci. 24(7):6388.
      [7] Kunc M et al. (2023): Histopathology. 83(1):3-14.
      [8] Cammareri C et al. (2023): Virchows Arch. 483(2):145-156.
      [9] Castillo P et al. (2023): Clin Exp Dermatol. llad405.
      [10] Lamas NJ et al. (2023): Pathology. 55(7):929-944.
      [11] Mudhar HS et al. (2023): Lab Invest. 104(1):100281.
      [12] Salleh AA et al. (2023): Ocul Oncol Pathol. 1-8.

    bottom of page